What is the recommended dose of Tamiflu (Oseltamivir) for influenza treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tamiflu (Oseltamivir) Dosing Recommendations

For adults and adolescents ≥13 years, the standard treatment dose is 75 mg orally twice daily for 5 days, and prophylaxis is 75 mg once daily for 10 days post-exposure or up to 6 weeks during community outbreaks. 1, 2, 3

Treatment Dosing

Adults and Adolescents (≥13 years)

  • 75 mg orally twice daily for 5 days 1, 2, 3
  • Initiate treatment within 48 hours of symptom onset for maximum effectiveness 2, 4
  • Earlier initiation provides greater benefit—starting within 12 hours of fever onset reduces illness duration by 3.1 days more than starting at 48 hours 4

Pediatric Patients (≥12 months to 12 years)

Weight-based dosing twice daily for 5 days: 1, 2, 3

  • ≤15 kg (≤33 lb): 30 mg twice daily
  • >15-23 kg (>33-51 lb): 45 mg twice daily
  • >23-40 kg (>51-88 lb): 60 mg twice daily
  • >40 kg (>88 lb): 75 mg twice daily

Infants (0-11 months)

  • 9-11 months: 3.5 mg/kg per dose twice daily for 5 days 1, 2
  • Term infants 0-8 months: 3 mg/kg per dose twice daily for 5 days 1, 2

Preterm Infants

Dosing based on postmenstrual age (gestational age + chronological age), twice daily for 5 days: 1, 2

  • <38 weeks: 1.0 mg/kg per dose
  • 38-40 weeks: 1.5 mg/kg per dose
  • >40 weeks: 3.0 mg/kg per dose

Prophylaxis Dosing

Adults and Adolescents (≥13 years)

  • 75 mg once daily for 10 days (post-exposure prophylaxis) 1, 3
  • 75 mg once daily for up to 6 weeks (seasonal/community outbreak prophylaxis) 1, 3
  • Up to 12 weeks in immunocompromised patients 3

Pediatric Patients (≥1 year to 12 years)

Use the same weight-based doses as treatment, but once daily instead of twice daily for 10 days: 1, 2

  • ≤15 kg: 30 mg once daily
  • 15-23 kg: 45 mg once daily

  • 23-40 kg: 60 mg once daily

  • 40 kg: 75 mg once daily

Infants (3-11 months)

  • 3 mg/kg once daily for 10 days 1, 2
  • Prophylaxis is not recommended for infants <3 months unless the situation is judged critical due to limited safety data 2

Renal Impairment Adjustments

For creatinine clearance 10-30 mL/min: 1, 2

  • Treatment: 75 mg once daily for 5 days
  • Prophylaxis: 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses)

Oseltamivir is not recommended for patients with end-stage renal disease not undergoing dialysis 3

Formulation and Administration

Available Forms

  • Capsules: 30 mg, 45 mg, 75 mg 1, 2
  • Oral suspension: 6 mg/mL when reconstituted 1, 2, 3

Suspension Dosing Volumes

  • 30 mg dose = 5 mL
  • 45 mg dose = 7.5 mL
  • 60 mg dose = 10 mL
  • 75 mg dose = 12.5 mL 1, 2

Administration Tips

  • Can be taken with or without food, but taking with food improves gastrointestinal tolerability 2, 3, 5
  • Capsules can be opened and contents mixed with liquid if patients cannot swallow capsules whole 2
  • If commercial suspension unavailable, pharmacies can compound using capsule contents mixed with simple syrup or Ora-Sweet SF to achieve 6 mg/mL concentration 2

Special Populations

Pregnancy

  • Pregnant women receive the same dosing as non-pregnant persons: 75 mg twice daily for 5 days 1
  • This applies throughout all trimesters and postpartum period (within 2 weeks after delivery) 1
  • Oseltamivir is preferred over zanamivir in pregnancy 1

Breastfeeding

  • Breastfeeding mothers can receive oseltamivir and should continue breastfeeding 1

Important Drug Interactions

Avoid live attenuated influenza vaccine (LAIV) within 48 hours before oseltamivir, and do not use oseltamivir for 14 days after LAIV vaccination 1, 2

Common Adverse Effects

  • Nausea and vomiting are the most common adverse events (5-15% of patients) 2, 5
  • Gastrointestinal effects are typically mild, transient, and occur primarily with first dosing 5, 4
  • Other adverse events include headache, diarrhea, and skin reactions 2
  • Overall discontinuation rate is low (1.8%) 4

Clinical Pearls

  • Treatment reduces illness duration by approximately 1-1.5 days (19-30% reduction) when started within 48 hours 6, 7
  • Earlier treatment provides progressively greater benefit—every hour counts 4
  • Oseltamivir reduces severity of symptoms by up to 38%, decreases secondary complications, and reduces antibiotic use 5, 6
  • Effective against both influenza A and B viruses 5, 6
  • Prophylaxis provides >70% protection in unvaccinated adults and 92% protection in vaccinated high-risk elderly patients 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.